Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(100.0%)
2Total
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03506269Completed

Perception and Knowledge About Menopause Among Pakistani Woman

Role: lead

NCT03506256Phase 4Unknown

Noroxin Efficacy and Safety Trial

Role: lead

NCT03486561Phase 4Unknown

Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)

Role: lead

NCT03473444Unknown

Prevalence of Hyperuricemia in Pakistan

Role: lead

All 4 trials loaded